Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

BACKGROUND: COVID-19 is associated with inflammation and an increased risk of thromboembolic complications. Prophylactic doses of low-molecular-weight heparin have been used in hospitalised and non-critically ill patients with COVID-19. We aimed to evaluate the efficacy and safety of prophylactic lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cools, Frank, Virdone, Saverio, Sawhney, Jitendra, Lopes, Renato D, Jacobson, Barry, Arcelus, Juan I, Hobbs, F D Richard, Gibbs, Harry, Himmelreich, Jelle C L, MacCallum, Peter, Schellong, Sebastian, Haas, Sylvia, Turpie, Alexander G G, Ageno, Walter, Rocha, Ana Thereza, Kayani, Gloria, Pieper, Karen, Kakkar, Ajay K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243570/
https://www.ncbi.nlm.nih.gov/pubmed/35779560
http://dx.doi.org/10.1016/S2352-3026(22)00173-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243570/
https://www.ncbi.nlm.nih.gov/pubmed/35779560
http://dx.doi.org/10.1016/S2352-3026(22)00173-9

Ejemplares similares